Investors Urged to Act: Class Action Lawsuit Against Skye Bioscience by Berger Montague

Class Action Alert: Skye Bioscience, Inc. (NASDAQ: SKYE)

Berger Montague PC, a leading national plaintiffs' law firm, has announced that a class action lawsuit has been initiated against Skye Bioscience, Inc. (NASDAQ: SKYE). This action targets investors who acquired Skye securities during the specified class period from November 4, 2024, through October 3, 2025. If you are a shareholder during this timeframe, you must act swiftly, as you have until January 16, 2026, to inquire about your rights and possibly join the class action as a lead plaintiff.

Background of the Case

Skye Bioscience is a biotechnology firm based in San Diego, concentrating on innovative therapies for obesity and metabolic disorders. The lawsuit claims that the company misrepresented the potential success of its leading drug candidate, nimacimab. Throughout the class period, investors were allegedly misled about the clinical trials and advancements related to nimacimab’s development.

The significant turning point in the case occurred on October 6, 2025, when Skye released the results of its Phase 2 clinical trial called the CBeyond trial. The findings revealed that the drug did not meet its primary weight-loss objective when compared to a placebo group. Notably, this announcement led to a shocking decline in Skye’s stock price, plummeting approximately 60% — from $4.75 to $1.90, equivalent to a loss of $2.85 per share.

Investor Options

Investors who have experienced losses due to the alleged mismanagement or misinformation surrounding this clinical trial are encouraged to come forward. Berger Montague is well-known for their expertise in handling complex litigation and has guided numerous investors through class actions successfully. They have recovered substantial settlements exceeding $50 billion over their 55 years of operation.

How to Get Involved

If you are a Skye investor and wish to learn more about participating in this class action, promptly reach out to Berger Montague. You can contact Andrew Abramowitz or Caitlin Adorni at the provided emails or phone numbers for detailed information regarding your rights and potential involvement in the lawsuit.

Berger Montague's Role

Established as one of the foremost law firms focusing on class actions and complex litigation, Berger Montague has a proven track record. They represent clients in multiple legal areas, including antitrust, consumer protection, and shareholder rights. Their commitment to transparency and advocacy for investors is a critical part of their mission.

Conclusion

The upcoming deadline on January 16, 2026, serves as a pivotal moment for investors affected by the alleged misrepresentations made by Skye Bioscience. As the details of the lawsuit unfold, affected individuals should consider consulting with legal representatives who specialize in securities fraud to understand their options better. As always, being informed and proactive is essential for securing your investment rights in complex litigation scenarios. For more inquiries, don’t hesitate to connect with Berger Montague and make your voice heard in the legal system for accountability and justice.